Announced details
Treatment of allergic conjunctivitis. 杏林製薬 will cover medical institutions outside ophthalmology, while SANTEN PHARMACEUTICAL CO.,LTD. will cover the ophthalmology field.
The companies entered into a co-promotion agreement in Japan on 13 July 2026. SANTEN PHARMACEUTICAL CO.,LTD. is responsible for manufacturing and marketing the product and promotion in the ophthalmology field, while 杏林製薬 is responsible for promotion to medical institutions outside ophthalmology.
Headquartered in Osaka, Japan, SANTEN PHARMACEUTICAL CO.,LTD. is a global pharmaceutical company specializing in ophthalmology. Founded in Osaka, Japan, in 1890, it conducts research and development, manufacturing and marketing of pharmaceuticals and medical devices in ophthalmology, and provides products and services in more than 60 countries and regions worldwide. Its product portfolio covers glaucoma, dry eye, infectious diseases, allergies, age-related macular degeneration and myopia.
If any matter requiring disclosure arises concerning the impact on the consolidated earnings outlook for the fiscal year ending March 2027, the company will disclose it promptly. No specific impact amount has been provided at this time.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Alesion® Eyelid Cream 0.5% |
| Counterparty | SANTEN PHARMACEUTICAL CO.,LTD. |
| Counterparty overview | Headquartered in Osaka, Japan, SANTEN PHARMACEUTICAL CO.,LTD. is a global pharmaceutical company specializing in ophthalmology. Founded in Osaka, Japan, in 1890, it conducts research and development, manufacturing and marketing of pharmaceuticals and medical devices in ophthalmology, and provides products and services in more than 60 countries and regions worldwide. Its product portfolio covers glaucoma, dry eye, infectious diseases, allergies, age-related macular degeneration and myopia. |
| Relationship with the Company | The companies entered into a co-promotion agreement in Japan on 13 July 2026. SANTEN PHARMACEUTICAL CO.,LTD. is responsible for manufacturing and marketing the product and promotion in the ophthalmology field, while 杏林製薬 is responsible for promotion to medical institutions outside ophthalmology. |
| Contract Date | 13 July 2026 |
| Launch date | 17 August 2026 (scheduled; start of promotional activities) |
| Applicable area | Treatment of allergic conjunctivitis. 杏林製薬 will cover medical institutions outside ophthalmology, while SANTEN PHARMACEUTICAL CO.,LTD. will cover the ophthalmology field. |
| Impact on Business Performance | If any matter requiring disclosure arises concerning the impact on the consolidated earnings outlook for the fiscal year ending March 2027, the company will disclose it promptly. No specific impact amount has been provided at this time. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.By combining 杏林製薬’s expertise in allergic diseases and its sales and marketing base in the respiratory and otolaryngology fields with SANTEN PHARMACEUTICAL CO.,LTD.’s expertise in ophthalmology, the companies aim to make Alesion Eyelid Cream available to more patients and contribute to improving their quality of life.